Comment

  • 27 January 2017

    CDK4/6 inhibitor rivalry in breast cancer begins

    Cyclin D kinase 4/6 (CDK4/6) inhibitors have shown great improvement in extending progression-free survival (PFS) in patients with human epidermal growth factor-negative (HER2-) and hormonal receptor positive (HR+) metastatic breast...

  • 2 August 2016

    Lupus breakthrough sparks hope in a frustrating field

    AstraZeneca has presented new positive clinical trial results for anifrolumab, an investigational monoclonal antibody that is under development for the treatment of moderate to severe lupus. Abi Millar speaks to...